Biopharma fundraising remains robust, with significant capital raised in public and private financings year-to-date and substantial recent funds closing, including Brandon Capital's AU$439 million sixth life sciences fund and Omega’s $647 million eighth fund. Market surveys reveal that companies are actively adjusting to tariffs, pricing shifts, and supply chain challenges with scenario planning and innovation strategy adaptations. Despite restructuring and layoffs in some hubs, the sector continues to secure investment and engage in strategic realignments to navigate evolving commercial landscapes.